高级检索
当前位置: 首页 > 详情页

Soluble form of immune checkpoints in autoimmune diseases

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Chengdu Fifth Peoples Hosp, Geriatr Dis Inst Chengdu, Dept Clin Lab, Chengdu, Sichuan, Peoples R China [2]Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Sichuan Geriatr Med Ctr, Geriatr Intens Care Unit, Chengdu, Sichuan, Peoples R China [3]Chengdu Fifth Peoples Hosp, Dept Training, Chengdu, Sichuan, Peoples R China [4]Chengdu Fifth Peoples Hosp, Dept Resp & Crit Care Med, Chengdu, Sichuan, Peoples R China [5]Chengdu Fifth Peoples Hosp, Geriatr Dis Inst Chengdu, Dept Geriatr, Chengdu, Sichuan, Peoples R China [6]Chengdu Fifth Peoples Hosp, Geriatr Dis Inst Chengdu, Dept Intens Care Med, Chengdu, Sichuan, Peoples R China [7]Chengdu Fifth Peoples Hosp, Ctr Med Res & Translat, Chengdu, Sichuan, Peoples R China
出处:
ISSN:

关键词: Soluble immune checkpoint Autoimmune disease Diagnosis Pathogenic mechanism

摘要:
Immune checkpoints are essential regulators of immune responses, either by activating or suppressing them. Consequently, they are regarded as pivotal elements in the management of infections, cancer, and autoimmune disorders. In recent years, researchers have identified numerous soluble immune checkpoints that are produced through various mechanisms and demonstrated biological activity. These soluble immune checkpoints can be produced and distributed in the bloodstream and various tissues, with their roles in immune response dysregulation and autoimmunity extensively documented. This review aims to provide a thorough overview of the generation of various soluble immune checkpoints, such as sPD-1, sCTLA-4, sTim-3, s4-1BB, sBTLA, sLAG-3, sCD200, and the B7 family, and their importance as indicators for the diagnosis and prediction of autoimmune conditions. Furthermore, the review will investigate the potential pathological mechanisms of soluble immune checkpoints in autoimmune diseases, emphasizing their association with autoimmune diseases development, prognosis, and treatment.

基金:

基金编号: LH202402002 2023459 XJ2023001102

语种:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2023]版:
大类 | 1 区 医学
小类 | 2 区 免疫学
最新[2023]版:
大类 | 1 区 医学
小类 | 2 区 免疫学
JCR分区:
出版当年[2023]版:
Q1 IMMUNOLOGY
最新[2023]版:
Q1 IMMUNOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2023版]

第一作者:
第一作者机构: [1]Chengdu Fifth Peoples Hosp, Geriatr Dis Inst Chengdu, Dept Clin Lab, Chengdu, Sichuan, Peoples R China
共同第一作者:
通讯作者:
通讯机构: [4]Chengdu Fifth Peoples Hosp, Dept Resp & Crit Care Med, Chengdu, Sichuan, Peoples R China [5]Chengdu Fifth Peoples Hosp, Geriatr Dis Inst Chengdu, Dept Geriatr, Chengdu, Sichuan, Peoples R China [6]Chengdu Fifth Peoples Hosp, Geriatr Dis Inst Chengdu, Dept Intens Care Med, Chengdu, Sichuan, Peoples R China [7]Chengdu Fifth Peoples Hosp, Ctr Med Res & Translat, Chengdu, Sichuan, Peoples R China [*1]33 Ma Shi St, Chengdu, Sichuan, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:43378 今日访问量:0 总访问量:3120 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号